Literature DB >> 10427466

Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes.

E Rey1, J M Tréluyer, G Pons.   

Abstract

All benzodiazepines enter cerebral tissue rapidly. However, the duration of action is short for diazepam (< 2 hours) and midazolam (3 to 4 hours) and longer for clonazepam (24 hours) and lorazepam (up to 72 hours), and is not correlated with the plasma concentration-time profiles of these drugs. Although a relationship between the plasma concentration of diazepam, lorazepam and midazolam and their pharmacodynamic effect has been demonstrated in healthy individuals, some caution is warranted as the clinical relevance of these data has not been clearly established. The physicochemical properties of benzodiazepines (lipid solubility and protein binding) regulate their rate and extent of entry into the brain and cerebrospinal fluid. However, the duration of the pharmacological activity of benzodiazepines may be in part related to the affinity of these compounds for the benzodiazepine receptors in the brain: midazolam, clonazepam and lorazepam have higher affinities than diazepam. In the emergency setting, the intravenous route is the most suitable, delivering adequate quantities of benzodiazepines as fast as possible. However, when intravenous administration is not available, rectal administration of a solution is a convenient method for diazepam, midazolam being the only one of these drugs that should be given intramuscularly. The assessment of the efficacy of benzodiazepines in the management of acute seizures and status epilepticus is mainly based on nonrandomized uncontrolled trials. According to the route of administration, the efficacy was 28.6 to 100% (intrarectal) and 54 to 100% (intravenous) for diazepam, 82 to 100% (intravenous) for lorazepam, and 79% (intranasal), 93 to 100% (intramuscular) and 100% (intravenous) for midazolam. Although diazepam was initially chosen for the management of refractory status epilepticus, the longer duration of action of lorazepam and clonazepam may favour the use of these 2 drugs. However, double-blind evaluations are necessary to determine which drug is best.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10427466     DOI: 10.2165/00003088-199936060-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  83 in total

1.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

Authors:  T Kronbach; D Mathys; M Umeno; F J Gonzalez; U A Meyer
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

2.  Cerebrospinal fluid concentrations and serum protein binding of lorazepam and its conjugate.

Authors:  L Aaltonen; J Kanto; M Salo
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-02

3.  Adsorption of benzodiazepines on charcoal and its correlation with in vitro and in vivo data.

Authors:  L K el-Khordagui; A M Saleh; S A KhalIl
Journal:  Pharm Acta Helv       Date:  1987

4.  CSF penetration and pharmacokinetics of midazolam.

Authors:  S Sjövall; J Kanto; J J Himberg; M Hovi-Viander; M Salo
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Brain uptake of phenytoin, phenobarbital, and diazepam.

Authors:  R E Ramsay; E J Hammond; R J Perchalski; B J Wilder
Journal:  Arch Neurol       Date:  1979-09

6.  Blood levels of diazepam after single rectal administration in infants and children.

Authors:  O Dulac; J Aicardi; E Rey; G Olive
Journal:  J Pediatr       Date:  1978-12       Impact factor: 4.406

Review 7.  Pharmacology of midazolam.

Authors:  L Pieri; R Schaffner; R Scherschlicht; P Polc; J Sepinwall; A Davidson; H Möhler; R Cumin; M Da Prada; W P Burkard; H H Keller; R K Müller; M Gerold; M Pieri; L Cook; W Haefely
Journal:  Arzneimittelforschung       Date:  1981

8.  Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism.

Authors:  E J Seree; P J Pisano; M Placidi; R Rahmani; Y A Barra
Journal:  Fundam Clin Pharmacol       Date:  1993       Impact factor: 2.748

9.  Lorazepam: a controlled trial in patients with intractable partial complex seizures.

Authors:  J E Walker; R W Homan; I L Crawford
Journal:  Epilepsia       Date:  1984-08       Impact factor: 5.864

10.  Midazolam: an effective intravenous agent for seizure control.

Authors:  G M Galvin; G A Jelinek
Journal:  Arch Emerg Med       Date:  1987-09
View more
  22 in total

1.  Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.

Authors:  P D Knoester; D M Jonker; R T M Van Der Hoeven; T A C Vermeij; P M Edelbroek; G J Brekelmans; G J de Haan
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

2.  Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study.

Authors:  Michael J Lamson; Diane Sitki-Green; Gerald L Wannarka; Michael Mesa; Paul Andrews; John Pellock
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis.

Authors:  Jason McMullan; Comilla Sasson; Arthur Pancioli; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-06       Impact factor: 3.451

4.  Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions.

Authors:  B R Ogutu; C R J C Newton; J Crawley; S N Muchohi; G O Otieno; G Edwards; K Marsh; G O Kokwaro
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

5.  Diagnosis and Treatment of Nonconvulsive Status Epilepticus in an Intensive Care Unit Setting.

Authors:  Stephan J. Rüegg; Marc A. Dichter
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

6.  Electroencephalographic effects and serum concentrations after intranasal and intravenous administration of diazepam to healthy volunteers.

Authors:  K Lindhardt; S Gizurarson; S B Stefánsson; D R Olafsson; E Bechgaard
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

7.  Inhibition of recombinant L-type voltage-gated calcium channels by positive allosteric modulators of GABAA receptors.

Authors:  Damien E Earl; Elizabeth I Tietz
Journal:  J Pharmacol Exp Ther       Date:  2011-01-24       Impact factor: 4.030

8.  Treatment of acute seizures: is intranasal midazolam a viable option?

Authors:  Lesley K Humphries; Lea S Eiland
Journal:  J Pediatr Pharmacol Ther       Date:  2013-04

9.  Development of benzodiazepines for out-of-hospital management of seizure emergencies.

Authors:  Suresh K Agarwal; James C Cloyd
Journal:  Neurol Clin Pract       Date:  2015-02

10.  Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.

Authors:  Mihir B Chauhan; Neelima B Chauhan
Journal:  J Neurol Neurosurg       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.